Summary
The product Clomiphene Citrate, manufactured by Imperium Pharma, underwent independent testing to verify its concentration and quality. The sample, identified with an unknown batch number, was submitted by Anonymous and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis determined that the Clomiphene Citrate concentration was 42.87 mg.
The testing process began on 15 January 2025, with the sample received on 21 January 2025, and analysis completed on 27 January 2025. While the results confirm the presence of Clomiphene Citrate, further scrutiny is necessary to ensure consistency across different batches. Independent third-party testing remains essential for comprehensive validation. This report is published as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Imperium Pharma
- Product Name: Clomiphene Citrate
- Active Ingredient: Clomiphene Citrate
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #56396
- Testing Ordered: 15 January 2025
- Sample Received: 21 January 2025
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Imperium Pharma (Manufacturer)
- Analysis Paid For By: Imperium Pharma (Manufacturer)
Testing Results
- Specification: 50 mg
- Measured Concentration: 42.87 mg
- Purity: Not provided
Verification Details
Verification URL: https://janoshik.com/tests/56396_FSK75J3NP6G7
Evaluation of Manufacturer-Submitted Testing
This analysis confirms that the tested product contains Clomiphene Citrate at a measured concentration of 42.87 mg. Since this sample was submitted anonymously, careful evaluation is required to assess product consistency across different batches. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, independent verification across multiple samples is recommended to establish broader reliability.
Conclusion
The analysis verifies the presence of Clomiphene Citrate at a concentration of 42.87 mg. While this result indicates the product’s potency, additional testing would be beneficial to ensure consistent dosing across different production batches. This report serves as an educational resource for harm reduction and informed decision-making in pharmaceutical use.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it still provides useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
